Abstract:Cardiovascular disease (CVD) is a major threat to human health, accounting for 46% of non-communicable disease deaths. Glycolysis is a conserved and rigorous biological process that breaks down glucose into pyruvate, and its primary function is to provide the body with the energy and intermediate products needed for life activities. The non-glycolytic actions of enzymes associated with the glycolytic pathway have long been found to be associated with the development of CVD, typically exemplified by metabolic remodeling in heart failure, which is a condition in which the heart exhibits a rapid adaptive response to hypoxic and hypoxic conditions, occurring early in the course of heart failure. It is mainly characterized by a decrease in oxidative phosphorylation and a rise in the glycolytic pathway, and the rise in glycolysis is considered a hallmark of metabolic remodeling. In addition to this, the glycolytic metabolic pathway is the main source of energy for cardiomyocytes during ischemia–reperfusion. Not only that, the auxiliary pathways of glycolysis, such as the polyol pathway, hexosamine pathway, and pentose phosphate pathway, are also closely related to CVD. Therefore, targeting glycolysis is very attractive for therapeutic intervention in CVD. However, the relationship between glycolytic pathway and CVD is very complex, and some preclinical studies have confirmed that targeting glycolysis does have a certain degree of efficacy, but its specific role in the development of CVD has yet to be explored. This article aims to summarize the current knowledge regarding the glycolytic pathway and its key enzymes (including hexokinase (HK), phosphoglucose isomerase (PGI), phosphofructokinase-1 (PFK1), aldolase (Aldolase), phosphoglycerate metatase (PGAM), enolase (ENO) pyruvate kinase (PKM) lactate dehydrogenase (LDH)) for their role in cardiovascular diseases (e.g., heart failure, myocardial infarction, atherosclerosis) and possible emerging therapeutic targets.

An Overview of Glycosylation and its Impact on Cardiovascular Health and Disease

O-GlcNAcylation, a Sweet Link to the Pathology of Diseases

Protein glycosylation in cardiovascular health and disease

Glycation and Glycosylation in Cardiovascular Remodeling: Focus on Advanced Glycation End Products and O-Linked Glycosylations as Glucose-Related Pathogenetic Factors and Disease Markers

Glycometabolism reprogramming: Implications for cardiovascular diseases

Glycosylation of HDL-Associated Proteins and Its Implications in Cardiovascular Disease Diagnosis, Metabolism and Function

Roles of O-GlcNAcylation in Mitochondrial Homeostasis and Cardiovascular Diseases

The role of glycolytic metabolic pathways in cardiovascular disease and potential therapeutic approaches

The multifaceted role of intracellular glycosylation in cytoprotection and heart disease

Emerging Roles of UDP-GalNAc Polypeptide N-Acetylgalactosaminyltransferases in Cardiovascular Disease

Glycosylation: mechanisms, biological functions and clinical implications

O‐GlcNAcylation: cellular physiology and therapeutic target for human diseases

The O-GlcNAc dichotomy: when does adaptation become pathological?

Glycation in the cardiomyocyte

Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis

Glycocalyx–Sodium Interaction in Vascular Endothelium

Glycosphingolipids in Cardiovascular Disease: Insights from Molecular Mechanisms and Heart Failure Models

Lactate metabolism and lactylation in cardiovascular disease: novel mechanisms and therapeutic targets

Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways

The Endothelial Glycocalyx: A Possible Therapeutic Target in Cardiovascular Disorders